555 Results
Sort By:
Published on April 15, 2016
Illumina is committing $100 million over 10 years to a new venture capital firm whose investment priorities will be in line with the company’s vision. Illumina said the new firm—to be called Illumina Ventures—will be managed independently of the sequencing giant. However, Illumina will be the majority limited partner in…
Published on March 1, 2016
The world’s first processor expressly designed to perform secondary analysis of next-generation sequencing data is relieving the bottleneck between sequencing and practical application. Setting a new standard for speedy analysis, the processor recently allowed a provider of clinical sequencing services to analyze sequenced genomes in just 26 minutes. Moreover, it…
Published on March 1, 2016
Targeted sequencing is an economical way to obtain sequencing reads that are limited only to genomic regions of interest. There are two different approaches used in targeted sequencing—exome capture and amplicon sequencing.1,2 While exome capture has advantages for whole-exome sequencing (30 Mb for the human genome), amplicon libraries offer more…
Published on February 25, 2016
The NIH has selected Vanderbilt University and Verily (formerly Google Life Sciences) to launch the first “pilot” phase of the Precision Medicine Initiative (PMI)'s planned research cohort of 1 million or more Americans from which to glean health and wellness data. The Vanderbilt-Verily partnership was announced today by President Obama's…
Published on February 12, 2016
Silicon Biosystems Menarini and Macrogen said today they will partner to co-develop clinical assays and procedures for precision medicine in cancer. The companies said their collaboration would combine Silicon Biosystems' DEPArray™ digital-sorting technology with Macrogen's whole-genome, whole-exome, and targeted sequencing capabilities, with the goal of developing CLIA-certified genomic cancer assays.…
Published on January 5, 2016
While the heterogeneity of influenza A infections has been understood for some time, the impact of minor strains on overall infection and transmission rates has been underappreciated. Now, a team of researchers led by scientists at New York University’s College of Global Public Health has discovered evidence strongly suggesting that…
Published on December 4, 2015
An NIH-funded study led by scientists at Harvard Medical School that were part of the Pediatric Cardiovascular Genetics Consortium have found a link for a set of gene mutations in the development of congenital heart disease and various neurodevelopmental abnormalities in children—include cognitive, motor, social, and language impairments. “We're homing…
Published on November 30, 2015
Human Longevity Inc. (HLI) said today it has acquired Cypher Genomics for an undisclosed price, in a deal that adds human genomic interpretation software solutions to the buyer’s offerings. Based in San Diego, Cypher Genomics is a genome informatics company that has developed and markets Mantis™, software designed to enable customers to…
Published on November 2, 2015
Tute Genomics said today it has acquired the human-genome interpretation company Knome for an undisclosed price. Co-founded by George Church, Ph.D., Knome provides human genome interpretation systems and services designed to help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Knome says its…
Published on October 15, 2015
Researchers from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard have harnessed the power of next-generation sequencing to analyze a large collection of leukemia tissue samples. Using whole exome sequencing (WES), the investigators screened genetic material from more than 500 samples of chronic lymphocytic leukemia (CLL)…
Published on August 26, 2015
While the incidence of acute myeloid leukemia (AML) is still relatively rare, accounting for approximately 1% of cancer deaths in the U.S., rates of occurrence are expected to rise as the largest portion of the population continues to age. Moreover, there remains a significant level of disparity in clinical outcomes,…
Published on July 17, 2015
Scientists at the Aortic Institute at Yale tested the genomes of more than 100 patients with thoracic aortic aneurysms, a potentially lethal condition, and provided genetically personalized care. They say their work will also lead to the development of a “dictionary” of genes specific to the disease, according to researchers.…
Published on July 2, 2015
I’ve been involved in lots of discussions about the future lately. Particularly the future of medicine, the future of data science, and how these topics merge around the potential for genomics to contribute to clinical care. It has long been anticipated, but that translation from science to treatment isn’t quite…
Published on May 14, 2015
Human Longevity (HLI) and the Cleveland Clinic agreed to collaborate to sequence and analyze blood samples from Cleveland Clinic's GeneBank study of de-identified patients. The two organizations will apply whole genome, cancer, and microbiome sequencing focusing on a subset of samples with the goal of discovering novel disease genes and…
Published on April 17, 2015
Scientists at the Ohio State University Comprehensive Cancer Center have developed a new method for measuring genetic variability within a tumor that might one day help doctors identify patients with aggressive cancers that are more likely to resist therapy. Researchers used a new scoring technique they developed called MATH (mutant-allele…